$64.84▾ 0.60%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
BioMarin Pharmaceutical Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days2 articles
2 bullish0 neutral0 bearish
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider
BioMarin Stops Voxzogo Development for Noonan Syndrome- How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
- BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development